{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:59:29Z","timestamp":1790135969000,"version":"4.0.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"9","funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"DOI":"10.1093\/jac\/dkx139","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T11:07:28Z","timestamp":1493204848000},"page":"2616-2626","source":"Crossref","is-referenced-by-count":156,"title":["Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections"],"prefix":"10.1093","volume":"72","author":[{"given":"Matthew","family":"Sims","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeri","family":"Mariyanovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"McLeroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Akers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chieh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Pedley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Kartsonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Paschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"key":"key\n\t\t\t\t20171012140003_dkx139-B1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/eri.13.12","article-title":"Clinical relevance of the ESKAPE pathogens","volume":"11","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/jac\/dks065","article-title":"Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis","volume":"67","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/JCM.03057-14","article-title":"Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs","volume":"53","year":"2015","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society, Infectious Diseases Society of America","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B5","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"50","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jinf.2011.05.015","article-title":"Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region","volume":"63","year":"2011","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B8","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B9","first-page":"165","article-title":"Vital signs: carbapenem-resistant Enterobacteriaceae","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B10","author":"CDC","year":"2013"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/CMR.05035-11","article-title":"Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions","volume":"25","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/INF.0b013e3181c9c118","article-title":"Carbapenemases: a brief review for pediatric infectious disease specialists","volume":"29","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1128\/AAC.41.3.563","article-title":"Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC \u03b2-lactamase, and the loss of an outer membrane protein","volume":"41","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B14","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1128\/AAC.46.11.3679-3682.2002","article-title":"Expression of SHV-2 \u03b2-lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems","volume":"46","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/eri.09.108","article-title":"Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy","volume":"8","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B16","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.50.5.1633-1641.2006","article-title":"Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates","volume":"50","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B17","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijantimicag.2015.08.011","article-title":"A resurgence of \u03b2-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens","volume":"46","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B19","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/AAC.05927-11","article-title":"In vitro activity of MK-7655, a novel \u03b2-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.bmcl.2013.12.101","article-title":"Discovery of MK-7655, a \u03b2-lactamase inhibitor for combination with Primaxin(R)","volume":"24","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B21","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of imipenem with relebactam against Gram-negative pathogens from New York City","volume":"59","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B22","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem\/cilastatin in subjects with complicated intra-abdominal infection","volume":"60","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijantimicag.2016.01.008","article-title":"Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013","volume":"47","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.diagmicrobio.2016.04.022","article-title":"Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014","volume":"85","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrurol.2015.199","article-title":"The emerging threat of multidrug-resistant Gram-negative bacteria in urology","volume":"12","year":"2015","journal-title":"Nat Rev Urol"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B26","first-page":"791","article-title":"Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study","volume":"32","year":"2014","journal-title":"World J Urol"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B27","doi-asserted-by":"crossref","first-page":"395.","DOI":"10.1186\/s12879-015-1123-5","article-title":"Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis","volume":"15","year":"2015","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B28","doi-asserted-by":"crossref","first-page":"596.","DOI":"10.1186\/s13054-014-0596-8","article-title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study","volume":"18","year":"2014","journal-title":"Crit Care"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B29"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B30","author":"Merck & Co I. PRIMAXIN\u00ae I.V. (Imipenem and Cilastatin for Injection)","year":"2014"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B31","volume-title":"US Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research (CDER) Guidance for Industry","author":"FDA","year":"1998"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B32","author":"EMA","year":"2011"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/clinids\/21.1.86","article-title":"A multicenter comparative study of meropenem and imipenem\/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients","volume":"21","year":"1995","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0002-9343(85)90107-X","article-title":"Safety and efficacy of imipenem\/cilastatin in treatment of complicated urinary tract infections","volume":"78","year":"1985","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B35","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.ijantimicag.2004.03.001","article-title":"Newer carbapenems for urinary tract infections","volume":"24","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B36","doi-asserted-by":"crossref","first-page":"S435","DOI":"10.1093\/clinids\/7.Supplement_3.S435","article-title":"Pharmacokinetics of imipenem and cilastatin in volunteers","volume":"7","year":"1985","journal-title":"Rev Infect Dis"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.26.5.707","article-title":"Disposition of radiolabeled imipenem and cilastatin in normal human volunteers","volume":"26","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B38","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1086\/427507","article-title":"Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults","volume":"40","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012140003_dkx139-B39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase 3 randomized trial program","volume":"63","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/9\/2616\/19540305\/dkx139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T23:06:36Z","timestamp":1658963196000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/72\/9\/2616\/3860014\/Prospective-randomized-doubleblind-Phase-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,6,1]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx139","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9]]},"published":{"date-parts":[[2017,6,1]]}}}